SCHEDULE 13D/A 0001493152-23-012282 0000898860 XXXXXXXX LIVE 6 Common Stock, par value $0.001 per share 09/30/2025 false 0001412486 19188J409 Cocrystal Pharma, Inc.

19805 N. CREEK PARKWAY BOTHELL WA 98011

Phillip Frost, M.D. (305) 575-6015 Frost Gamma Investments Trust 4400 Biscayne Boulevard Miami FL 33137 0000898860 N Phillip Frost, M.D. PF N X1 1382873.00 0.00 1382873.00 0.00 1382873.00 N 10.6 IN (1) 1,319,838 shares of the Issuer's common stock are held by Frost Gamma Investments Trust, which is controlled by Dr. Frost as sole trustee. Does not include options to acquire 47,792 shares of common stock, which are exercisable within 60 days. (2) Includes (i) 1,319,838 shares of the Issuer's common stock held by Frost Gamma Investments Trust, which is controlled by Dr. Frost as sole trustee; and (ii) options to acquire 47,792 shares of common stock, which are exercisable within 60 days. (3) Based on (i) 13,039,348 shares of common stock outstanding as of September 29, 2025 and (ii) 47,792 shares of common stock issuable upon exercise of options exercisable within 60 days. The percentage reflected in the table above is rounded to the nearest tenth (one place after the decimal point) in accordance with the instructions to Schedule 13D. 0001380896 N Frost Gamma Investments Trust PF N FL 1319838.00 0.00 1319838.00 0.00 1319838.00 N 10.1 OO (1) Based upon 13,039,348 shares of common stock outstanding as of September 29, 2025. The percentage reflected in the table above is rounded to the nearest tenth (one place after the decimal point) in accordance with the instructions to Schedule 13D. Common Stock, par value $0.001 per share Cocrystal Pharma, Inc. 19805 N. CREEK PARKWAY BOTHELL WA 98011 This Amendment is filed on behalf of Phillip Frost, M.D. and FGIT (together, the "Reporting Persons"). The principal business address of the Reporting Persons is 4400 Biscayne Boulevard, Miami, Florida 33137. During the last five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). During the last five years, none of the Reporting Persons (or their directors, officers, or controllers, if applicable) have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws. Dr. Frost is a citizen of the United States of America. FGIT was organized in the State of Florida. On August 21, 2025, the Reporting Person acquired 13,550 shares of the Issuer's common stock in connection with the vesting of restricted stock units. On September 30, 2025, the Reporting Person acquired 1,693 shares of the Issuer's common stock in connection with the vesting of restricted stock units. The Reporting Persons acquired the shares of common stock for investment purposes. On August 21, 2025, the Reporting Person acquired 13,550 shares of the Issuer's common stock upon vesting of restricted stock units. On September 30, 2025, the Reporting Person acquired 1,693 shares of the Issuer's common stock in connection with the vesting of restricted stock units. These securities are held by FGIT, of which Phillip Frost, MD is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of FGIT. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole shareholder of Frost-Nevada Corporation. Dr. Frost disclaims beneficial ownership of the securities held by FGIT except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose. The beneficial ownership percentages disclosed below are based on 13,039,348 shares of common stock outstanding as of September 29, 2025. Dr. Frost is the beneficial owner of 1,382,873 shares of common stock representing 10.6% of the shares outstanding of the Issuer, including (i) 1,319,838 shares of common stock held by FGIT, (ii) 15,243 shares of the Issuer's common stock held by the Reporting Person and (iii) 47,792 shares of common stock issuable upon exercise of vested options. Dr. Frost is the trustee of FGIT. Frost Gamma Limited Partnership is the sole and exclusive beneficiary of FGIT. Dr. Frost is one of two limited partners of Frost Gamma Limited Partnership. Dr. Frost is the sole shareholder of Frost-Nevada Corporation, which is the sole shareholder of Frost Gamma, Inc., the general partner of Frost Gamma Limited Partnership. As a result of the foregoing, Dr. Frost may be deemed the beneficial owner of the shares of common stock held by FGIT. Dr. Frost disclaims beneficial ownership of the securities held by FGIT except to the extent of any pecuniary interest therein. Dr. Frost has sole dispositive power with respect to 47,792 shares of common stock issuable upon exercise of vested options. The Reporting Persons have voting and dispositive power over the Issuer's securities as described above in Item 5(a). Except as described in this Schedule 13D under Item 3 above, the Reporting Persons did not engage in any transactions in shares of the Company's common stock during the past 60 days. Not Applicable. Not Applicable. Not Applicable. None. Phillip Frost, M.D. /s/ Phillip Frost, M.D. 10/02/2025 Frost Gamma Investments Trust /s/ Phillip Frost, M.D. 10/02/2025